CCR4 Ctcl - Search

About 37,700 results

Any time

Open links in new tab

PubMed
https://pubmed.ncbi.nlm.nih.gov
CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a ...
The interaction of CCR4 with its dominant ligands CCL17 and CCL22 plays a critical role in the development and progression of CTCL, facilitating the movement into, and accumulation of, …
- Author: Jan P. Nicolay, Jan P. Nicolay, Jana D. Albrecht, Jana D. Albrecht, Silvia Alberti-Violetti, Emilio ...
- Publish Year: 2021
Other content from pubmed.ncbi.nlm.nih.gov
See more
nih.gov
https://pmc.ncbi.nlm.nih.gov › articles
CCR4 expression in CD8+ cutaneous T-cell lymphomas and ...
We examined C-C chemokine receptor 4 (CCR4) expression as a diagnostic and therapeutic biomarker in CD8+ CTCL/LPDs.
Videos of CCR4 CTCL

bing.com › videos
Watch video on YouTube
7:30
POTELIGEO and the CCR4 Target
524 viewsMay 31, 2022
YouTubePOTELIGEO® (mogamulizumab-kpkc)
Watch video on YouTube
5:06
POTELIGEO Mechanism of Action
1.4K viewsMay 31, 2022
YouTubePOTELIGEO® (mogamulizumab-kpkc)
Watch video
3:32
Cutaneous T-Cell Lymphoma (CTCL) Treatment Options
28 viewsMar 3, 2022
YouTubeCheckRare
Watch video
4:54
Understanding Cutaneous T-cell Lymphoma (CTCL)
6.7K viewsSep 14, 2023
YouTubeThe Leukemia & Lymphoma Society of Canada
nih.gov
https://pmc.ncbi.nlm.nih.gov › articles
A Narrative Review of the State of the Art of CCR4-Based …
The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to its role in impairing immune responses against malignant T-cells and expression profiles. Monoclonal antibodies like mogamulizumab effectively bind to CCR4, reducing tumour burden and enhancing patient outcomes by inhibiting the receptor’s interaction ...
American Society of Hematology
https://ashpublications.org › blood › article
Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates …
Dec 7, 2017 · Mogamulizumab (Moga) is a monoclonal antibody directed against chemokine receptor 4 (CCR4), which is overexpressed on malignant T-cells. In a Phase I-II study in …
- Author: Youn H. Kim, Martine Bagot, Lauren Pinter-Brown, Alain H. Rook, Pierluigi Porcu, Steven M. Horwitz, ...
- Publish Year: 2017
Wiley Online Library
https://onlinelibrary.wiley.com › doi
CCR4 in cutaneous T‐cell lymphoma: Therapeutic …
CCR4 has several CCLs: CCL3, CCL5, CCL17, and CCL22. The most important CCLs for the pathogenesis of CTCL, and the primary ligands for CCR4, are …
Author: Jan P. Nicolay, Jan P. Nicolay, Jana D. Albrecht, Jana D. Albrecht, Silvia Alberti-Violetti, Emilio ...
Publish Year: 2021
nih.gov
https://pmc.ncbi.nlm.nih.gov › articles
CCR4 as a Therapeutic Target for Cancer …
Mogamulizumab is a fully humanized and glyco-engineered monoclonal anti-CCR4 antibody used for the treatment of refractory/relapsed ATLL and CTCLs, often resulting in complete remission. The clinical applications of …
People also ask
What is CC chemokine receptor 4 (CCR4)?
CC chemokine receptor 4 (CCR4) is highly expressed in many mature T-cell malignancies, such as adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL), and has a unique expression profile in normal T cells.
Identifying highly active anti-CCR4 CAR T cells for the
ashpublications.org
Can CCR4 treat cutaneous T-cell lymphoma (CTCL)?
New treatments are needed for patients with cutaneous T-cell lymphoma (CTCL), particularly for advanced mycosis fungoides (MF) and Sezary syndrome (SS). The immunopathology of MF and SS is complex, but recent advances in tumor microenvironment understanding have identified CCR4 as a promising therapeutic target.
CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a ... - Pub…
pubmed.ncbi.nlm.nih.gov
How does CCR4 interact with CCL17 and CCL22?
The interaction of CCR4 with its dominant ligands CCL17 and CCL22 plays a critical role in the development and progression of CTCL, facilitating the movement into, and accumulation of, CCR4-expressing T cells in the skin, and recruiting CCR4-expressing Tregs into the tumor microenvironment.
CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a ... - Pub…
pubmed.ncbi.nlm.nih.gov
What is the expression of CCR4 in HTLV-1-infected T cells?
This review overviews the expression of CCR4 in various T cell subsets, HTLV-1-infected T cells, ATLL and CTCLs, and the clinical applications of Mogamulizumab. CCR4 is a chemokine receptor mainly expressed by T cells. It is the receptor for two CC chemokine ligands, CCL17 and CCL22.
CCR4 as a Therapeutic Target for Cancer Immunotherapy - PMC
pmc.ncbi.nlm.nih.gov
What are ccr4-targeted therapies?
Several CCR4-targeted therapies are being evaluated, including “chemotoxins” targeting CCR4 via CCL17, CCR4-directed chimeric antigen receptor-modified T-cell therapies, small-molecule CCR4 antagonists, and anti-CCR4 monoclonal antibodies.
CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathog…
onlinelibrary.wiley.com
How does CCR4 car affect T-cell lymphoma cytotoxicity?
Fratricide induced by CCR4 CAR selectively depletes Th2, Th17, and Treg while sparing Th1. A challenge when targeting T-cell lymphoma with chimeric antigen receptor (CAR) T-cell therapy is that target antigens are often shared between T cells and tumor cells, resulting in fratricide between CAR T cells and on-target cytotoxicity on normal T cells.
Identifying highly active anti-CCR4 CAR T cells for the
ashpublications.org
Feedback
PubMed
https://pubmed.ncbi.nlm.nih.gov
A Narrative Review of the State of the Art of CCR4-Based
Apr 22, 2024 · The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to its role in impairing immune responses against malignant T-cells and …
National Center for Biotechnology Information
https://www.ncbi.nlm.nih.gov › pmc › articles
A Narrative Review of the State of the Art of CCR4-Based …
The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to its role in impairing immune responses against malignant T-cells and expression profiles. …
- DOI: 10.3390/antib13020032
- Published: 2024/06
- Publication: Antibodies (Basel). 2024 Jun; 13(2): 32.
nih.gov
https://pubmed.ncbi.nlm.nih.gov
Differential CCR4 expression and function in cutaneous T-cell ... - PubMed
Using cell lines originally derived from patients with different subtypes of CTCL, we have shown higher CCR4 expression in the line derived from the mycosis fungoides (MJ), compared with …
American Society of Hematology
https://ashpublications.org › ...
Identifying highly active anti-CCR4 CAR T cells for the treatment of …
Jul 12, 2023 · CC chemokine receptor 4 (CCR4) is highly expressed in many mature T-cell malignancies, such as adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell …
Pagination
- 1
- 2
- 3
- 4
- Next

CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a ...

CCR4 expression in CD8+ cutaneous T-cell lymphomas and ...

Videos of CCR4 CTCL

A Narrative Review of the State of the Art of CCR4-Based …

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates …

CCR4 in cutaneous T‐cell lymphoma: Therapeutic …

CCR4 as a Therapeutic Target for Cancer …

Identifying highly active anti-CCR4 CAR T cells for the

CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a ... - Pub…

CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a ... - Pub…

CCR4 as a Therapeutic Target for Cancer Immunotherapy - PMC

CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathog…

Identifying highly active anti-CCR4 CAR T cells for the

A Narrative Review of the State of the Art of CCR4-Based

A Narrative Review of the State of the Art of CCR4-Based …

Differential CCR4 expression and function in cutaneous T-cell ... - PubMed

Identifying highly active anti-CCR4 CAR T cells for the treatment of …

Explore more